Impaired antigen presentation by human monocytes during endotoxin tolerance

Blood

Volumn 96, Issue 1, 2000, Pages 218-223

  Wolk, Kerstin ^a   Döcke, Wolf Dietrich ^a   Von Baehr, Volker ^a   Volk, Hans Dieter ^a   Sabat, Robert ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; ENDOTOXIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INJURY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MAJOR SURGERY; MONOCYTE; PRIORITY JOURNAL; SEPTIC SHOCK; T LYMPHOCYTE ACTIVATION;

EID: 0342626639     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.218.013k04_218_223     Document Type: Article

References (37)

1. Freudenberg MA, Galanus C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun. 1988;56: 1352-1357.
2. Haas JG, Baeuerle PA, Riethmüller G, Ziegler-Heitbrock HWL. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci U S A. 1990;87:9563-9567
3. Ziegler-Heitbrock HWL, Blumenstein M, Käferlein E, et al. In vitro desensitization to lipopolysaccharide suppresses tumor necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology. 1992;75:246-268.
4. Zhang X, Morrison DC. Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages. J Exp Med. 1993;177:511-516.
5. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995;181:1887-1892.
6. Karp CL, Wysocka M, Ma X, et al. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur J Immunol. 1998;28:3128-3136.
7. Henricson BE, Manthey CL, Perera PY, et al. Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immun. 1993;61:2325-2333.
8. Cavaillon JM, Pitton C, Fitting C. Endotoxin tolerance is not a LPS-specific phenomenon: partial mimicry with IL-1, IL-10 and TGF-β. J Endotoxin Res. 1994;1:21-29.
9. Folkman J, Moscona A. Role of cell shape in growth control. Nature. 1978;273:345-349.
10. Sabat R, Seifert M, Volk HD, Glaser RW. Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Mol Immunol. 1996;33:1103-1111.
11. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 1994;76:287-299.
12. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998;18:389-418.
13. Linsley PS, Brady W, Grosmaire L, et al. Binding ol the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991;173:721-730.
14. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16: 111-135.
15. + T cell responses to CD40-deficient APCs: defects in proliferation and negative selection apply only with B cells as APCs. J Immunol. 1999;163:5250-5256.
16. Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 1995;15: 235-253.
17. + T cells are poorly costimulated by ICAM-1. Eur J Immunol. 1999;29:45-53.
18. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989;159:195-204.
19. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991; 174:1209-1220.
20. de Waal Malefyt R, Haanen J, Spits H. et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915-924.
21. Creery WD, Diaz-Mitoma F, Filion L, Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol. 1996;26:1273-1277.
22. Willems F, Marchant A, Delville JP, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol. 1994;24:1007-1009.
23. Poe JC, Wagner DH Jr, Miller RW, Stout RD, Suttles J. IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1β synthesis and rescue from apoptosis. J Immunol. 1997; 159:846-852.
24. Valitutti S, Muller S, Dessing M, Lanzavecchia A, Different responses are elicited in cytotoxic T lymphocytes by different levels of T-cell receptor occupancy. J Exp Med. 1996;183:1917-1921.
25. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-2412.
26. Satomi N, Haranaka K, Kunii O. Research on the production site of tumor necrosis factor (TNF). Jpn J Exp Med. 1981;51:317-322.
27. Sicher SC, Chung GW, Vazquez MA, Lu CY. Augmentation or inhibition of IFN-gamma-induced MHC class II expression by lipopolysaccharides: the roles of TNF-alpha and nitric oxide, and the importance of the sequence of signaling. J Immunol. 1995;155:5826-5834.
28. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
29. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218-220.
30. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 1996;22: S474-481.
31. Asadullah K. Woiciechowsky C, Döcke WD, et al. Immunodepression following neurosurgical procedures. Crit Care Med. 1995;23:1976-1983.
32. Woiciechowsky C, Asadullah K, Nestler D, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med. 1998;4:808-813.
33. Volk HD, Thieme M, Heym S, et al. Alterations in function and phenotype of monocytes from patients with septic disease - predictive value and new therapeutic strategies. Bering Inst Mitt. 1991; 88:208-215.
34. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3:678-681.
35. Volk HD, Lohmann T, Heym S, et al. Decrease of the proportion of the HLA-DR + monocytes as prognostic parameter for the clinical outcome of septic disease. In: Masihi KN, Lange W, eds. Immunotherapeutic prospects of infectious disease. Berlin: Springer-Verlag; 1990:298-301.
36. Asadullah K, Woiciechowsky C, Döcke WD, et al. Very low monocytic HLA-DR expression indicates high risk of infection - immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med. 1995;2: 184-190.
37. Marchant A, Deviere J, Byl B, et al. Interleukin-10 production in septicaemia. Lancet. 1994;343:707-708.